Transitional states of sarcopenia: the trajectory of fat accumulation and glucose fluctuation on risk of metabolic syndrome

• Published in: Annals of the New York Academy of Sciences Vol. 1503; no. 1; pp. 60 - 71
• Main Authors: Wu, Shou‐En, Chen, Wei‐Liang
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2021
• Subjects: Body fat; body fat percentage; Diabetes mellitus; Gene set enrichment analysis; Glucose; glucose instability; Hypertension; Metabolic disorders; Metabolic syndrome; muscle mass; Muscles; Sarcopenia; Skeletal muscle; Subgroups; transition; glucose instability; muscle mass; body fat percentage; transition; sarcopenia
• ISSN: 0077-8923; 1749-6632; 1749-6632
• DOI: 10.1111/nyas.14607

The association between sarcopenia and metabolic syndrome (MetS) has been well established. Nevertheless, the transition process between normal and low muscle mass (LMM) states and the effect of this transition on MetS has been less explored. Our study here examined whether the direction toward or away from LMM alters the risks of MetS. Initially, gene set enrichment analysis confirmed that MetS correlates with sarcopenia at the genetic level. Subsequently, 6476 eligible participants older than 60 years were enrolled between 2010 and 2016 at Tri‐Service General Hospital, Taiwan for evaluation. We discovered an inverse association between the skeletal muscle mass percentage and the risk of MetS. Participants were categorized into four subgroups: state 1 (normal→normal), state 2 (LMM→normal), state 3 (normal→LMM), and state 4 (LMM→LMM). State 4 had increased hazard ratios (HRs) of MetS, while state 2 revealed decreased HRs of MetS, hypertension (HTN), and type II diabetes mellitus (T2DM). State 2 also showed decreased HRs for all five MetS components. Despite the fact that state 3 did not reach statistical significance, increased body fat percentage and glucose fluctuation were observed in this group. The transition direction toward LMM (states 3 and 4) showed deterioration in metabolic indices, leading to increased HRs for MetS, HTN, and T2DM. Conducting timely intervention during this transition process may effectively prevent adverse events accompanying LMM. The association between sarcopenia and metabolic syndrome (MetS) has been well established. Nevertheless, the transition process between normal muscle mass and low muscle mass (LMM) states and the effect of this transition on MetS has been less explored. Here, we investigated the changes in metabolic indices within the transition process and examined improvement in, or deterioration of, MetS depending on the direction toward or away from LMM. Evidence of the modifiability of LMM and MetS may, we hope, encourage active lifestyle changes in patients and positive treatment strategies by physicians.